NRx Pharmaceuticals, Inc. NRXP

NRx Pharmaceuticals reports FDA revision of a prior major amendment to minor status for preservative-free Ketamine. FDA downgrade from major to minor amendment shortens review timeline and raises odds of faster Ketamine approval.

NRx Pharmaceuticals' GeNeuro subsidiary awarded European patent rights for GNK-301, a novel ALS drug candidate. Patent grant on novel ALS candidate bolsters NRx IP position and long-term drug development prospects.

NRx Pharmaceuticals subsidiary HOPE Therapeutics begins training and deployment of Zeta Surgical's FDA-cleared robotic TMS system. Subsidiary deployment of robotic TMS technology supports expanded NRx treatment capabilities with moderate operational effects.

NRx Pharmaceuticals, Inc. held its Q2 2026 earnings call, reporting financial results, operational updates, and forward-looking guidance for the company. Q2 2026 earnings call delivers key financial metrics and strategic guidance that can materially shift investor sentiment and company trajectory.

NRx Pharmaceuticals Inc advances ketamine pipeline per Q2 2026 earnings call highlights. Ketamine pipeline advancement signals major strategic progress with potential to shift company trajectory and investor sentiment.

NRx Pharmaceuticals reported second quarter 2026 financial results and issued a corporate update. A conference call is scheduled for August 17th at 4:30pm ET. Quarterly financial results and updates deliver data on performance that moderately shapes market views and company path.

NRx Pharmaceuticals nears FDA decision on preservative-free ketamine after review clears hurdles. Nearing FDA decision on preservative-free ketamine positions NRx for major shifts in market trajectory and investor outlook.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) schedules conference call August 10 to discuss FDA first-cycle ANDA review results and commercial plans. FDA ANDA review discussion points to imminent regulatory decision that can enable product launch and revenue generation.

FDA completes first-cycle review of NRx Pharmaceuticals preservative-free ketamine ANDA with no major drug-related deficiencies and requests only final packaging certification for approval. Near-approval status for key ketamine product advances regulatory path and supports future revenue potential.

NRx Pharmaceuticals, Inc. (NRXP) evaluates stock growth potential through innovations in depression and PTSD treatments. Treatment innovations in depression and PTSD may moderately affect NRx Pharmaceuticals financial performance and competitive positioning.

Kadima Neuropsychiatry Institute sues NRx Pharmaceuticals alleging breach of contract and misrepresentation tied to an acquisition. Acquisition-related lawsuit creates legal costs and potential liabilities that may pressure near-term finances and sentiment.

NRx Pharmaceuticals receives FDA expanded access protocol for D-Cycloserine-based NRX-101 to augment transcranial magnetic stimulation in depression treatment. FDA expanded access for NRX-101 in TMS augmentation advances clinical use and opens commercialization pathways for NRx Pharmaceuticals.

NRX Pharmaceuticals Inc highlighted strategic advances during its Q1 2026 earnings call. Strategic advances from earnings call will significantly alter company trajectory.

NRx Pharmaceuticals closed an underwritten public offering of common stock at $3.50 per share. Stock offering supplies NRx Pharmaceuticals with fresh capital while increasing share dilution.

NRx Pharmaceuticals closed a $22.3 million public offering of common stock including full exercise of the underwriters' option. The equity raise supplies fresh capital that supports operations and may influence near-term financial flexibility.

NRx Pharmaceuticals priced a public offering of common stock to raise capital. Stock offering supplies operating cash while diluting existing shares.

NRx Pharmaceuticals, Inc. announces proposed public offering of common stock. Proposed common stock offering enables capital raise while introducing share dilution that influences near-term valuation.

NRx Pharmaceuticals strategic partner Emobot presents late-breaking clinical validation of EMOCARE Depression Thermometer at ASCP 2026. Emobot validation of depression tool adds indirect CNS positioning support for NRx.

NRx Pharmaceuticals subsidiary HOPE Therapeutics becomes first commercial site to deploy Zeta Surgical's FDA-cleared Zeta TMS Navigation System. First commercial deployment of navigation system by HOPE Therapeutics may improve TMS treatment capabilities and support NRx positioning.

NRx Pharmaceuticals reported Q1 results in its earnings call, detailing financial performance, operational updates, and pipeline progress for NRXP. Q1 earnings updates typically influence short-term sentiment and operational outlook without major strategic shifts.

NRx Pharmaceuticals reported first quarter 2026 financial results and provided a corporate update. Quarterly results and updates offer performance data that can shift near-term investor views without guaranteeing major strategic shifts.

NRx Pharmaceuticals (Nasdaq:NRXP) announces FDA clearance to proceed with a clinical trial of NRX-101 combined with robotic-enabled Transcranial Magnetic Stimulation for patients with depression and suicidality. FDA clearance for a clinical trial targeting depression and suicidality advances NRx Pharmaceuticals' key drug candidate and could significantly enhance investor sentiment and market performance.

NRx Pharmaceuticals (Nasdaq:NRXP) announces initiation of commercial manufacturing for preservative-free ketamine, a key step toward potential market availability. Initiation of commercial manufacturing advances NRXP toward product commercialization, significantly boosting development pipeline and investor interest.

New to The Street Show #748 featured high-impact CEO interviews and spotlight TV commercials for NRx Pharmaceuticals, broadcast across Bloomberg to over 250 million households worldwide. TV exposure to 250M+ households boosts NRXP visibility and could moderately influence short-term market sentiment.

NRx Pharmaceuticals reports positive feedback from the FDA Office of Generic Drugs on its preservative-free ketamine program. Positive FDA feedback on preservative-free ketamine advances NRXP's generic drug pipeline toward potential approval and revenue generation.

NRx Pharmaceuticals (Nasdaq:NRXP) welcomes a presidential initiative to accelerate FDA approval of psychedelic medications for depression, PTSD, and suicidality, aligning with its pipeline for innovative mental health treatments. Presidential push for faster psychedelic drug approvals directly supports NRXP's pipeline for depression, PTSD, and suicidality treatments, potentially accelerating regulatory timelines and enhancing market prospects.

NRx Pharmaceuticals, Inc. (NRXP) advances robotic-enabled Transcranial Magnetic Stimulation (TMS) combined with Neuroplastic Therapy for treating conditions in military personnel and first responders. Innovative neuromodulation therapy targeting military and first responder markets positions NRXP for major government contracts and revenue growth.

NRx Pharmaceuticals (Nasdaq:NRXP) appoints Glenn Tyson as its first Chief Commercial Officer. Appointing the first Chief Commercial Officer marks a major strategic move to build commercialization capabilities, potentially accelerating revenue growth and improving market positioning.

NRx Pharmaceuticals (Nasdaq:NRXP) announces FDA labeling alignment for its preservative-free ketamine application, advancing regulatory progress for the treatment. FDA labeling alignment marks a significant regulatory milestone for NRx's key preservative-free ketamine product, potentially accelerating approval and enhancing market position.

Hope Therapeutics, NRx Pharmaceuticals (NRXP) subsidiary, announces strategic partnership with Emobot to integrate AI-powered 'Depression Thermometer' across its interventional psychiatry network. Partnership integrates AI depression detection into NRXP subsidiary's psychiatry network, moderately enhancing innovation and competitive positioning.